首页|期刊导航|实用肝脏病杂志|GLP-1受体激动剂治疗2型糖尿病合并非酒精性脂肪性肝炎患者临床疗效研究

GLP-1受体激动剂治疗2型糖尿病合并非酒精性脂肪性肝炎患者临床疗效研究OA

Glucagon-like peptide-1 receptor agonist in the treatment of patients with type 2 diabetes mellitus and concomitant non-alcoholic steatohepatitis

中文摘要英文摘要

目的 探讨胰高血糖素样肽-1受体激动剂(GLP-1RA)治疗2型糖尿病(T2DM)合并非酒精性脂肪性肝炎(NASH)患者的临床疗效及其对脂代谢的影响.方法 2021年5月~2024年12月我院诊治的T2DM合并NASH患者83例,被随机分为观察组42例和对照组41例,分别给予司美格鲁肽联合常规降糖治疗或单纯常规降糖治疗24周.常规检测糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后2小时血糖(2hPG)和血脂水平,采用ELISA法检测血清肿瘤坏死因子α(TNF-α)、白介素-6(IL-6)和C反应蛋白(CRP)水平,使用瞬时弹性成像仪行受控衰减参数(CAP)和肝脏硬度检测(LSM).结果 治疗后,观察组血清 FPG、2hPG、HbA1c 和 HOMA-IR 水平分别为(6.1±0.8)mmol/L、(7.6±1.7)mmol/L、(6.1±0.7)%和(3.5±0.7),均显著低于对照组[分别为(7.1±1.0)mmol/L、(9.2±1.9)mmol/L、(6.8±0.8)%和(4.6±0.9),P<0.05];观察组CAP和LSM水平分别为(288.5±20.7)dB/m和(9.1±1.3)kPa,均显著低于对照组[分别为(324.6±26.8)dB/m 和(11.5±1.5)kPa,P<0.05];观察组血清 TG、TC 和 LDL-C 水平分别为(2.4±0.8)mmol/L、(4.6±0.8)mmol/L 和(3.0±0.5)mmol/L,均显著低于对照组[分别为(2.9±0.7)mmol/L、(5.1±0.8)mmol/L 和(3.4±0.5)mmol/L,P<0.05];观察组血清TNF-α、IL-6和CRP水平分别为(9.1±1.9)pg/mL、(6.3±1.3)pg/mL和(3.6±0.9)mg/L,均显著低于对照组[分别为(14.1±2.6)pg/mL、(10.2±1.8)pg/mL 和(6.3±1.3)mg/L,P<0.05].结论 GLP-1RA 治疗可显著改善 T2DM合并NASH患者糖脂代谢异常,可能与减轻了机体炎症反应有关.

Objective The purpose of this study was to investigate clinical efficacy of glucagon-like peptide-1 receptor agonist(GLP-1RA)in the treatment of patients with type 2 diabetes mellitus(T2 DM)and concomitant non-alcoholic steatohepatitis(NASH).Methods 83 patients with T2DM and NASH were encountered in our hospital between May 2021 and December 2024,and were randomly assigned to receive metformin in 41 cases in control,or to receive semaglutide at base of metformin treatment in another 42 cases in observation for 24 weeks.Glycated hemoglobin(HbA1c),fasting plasma glucose(FPG),2-hour postprandial glucose(2hPG),triglyceride(TG),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C)and high-density lipoprotein cholesterol(HDL-C)levels were routinely detected.Serum C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)levels were assayed by ELISA.Controlled attenuation parameter(CAP)and liver stiffness measurement(LSM)were determined by Fibrotouch.Results By end of six-month treatment,FPG,2hPG,HbA1c and insulin resistance index(HOMA-IR)in the observation group were(6.1±0.8)mmol/L,(7.6±1.7)mmol/L,(6.1±0.7)%and(3.5±0.7),all much lower than[(7.1±1.0)mmol/L,(9.2±1.9)mmol/L,(6.8±0.8)%and(4.6±0.9),respectively,P<0.05]in the control;CAP and LSM were(288.5±20.7)dB/m and(9.1±1.3)kPa,both significantly lower than[(324.6±26.8)dB/m and(11.5±1.5)kPa,respectively,P<0.05]in the control;serum TG,TC and LDL-C levels were(2.4±0.8)mmol/L,(4.6±0.8)mmol/L and(3.0±0.5)mmol/L,all much lower than[(2.9±0.7)mmol/L,(5.1±0.8)mmol/L and(3.4±0.5)mmol/L,respectively,P<0.05]in the control;serum TNF-α,IL-6 and CRP levels were(9.1±1.9)pg/mL,(6.3±1.3)pg/mL and(3.6±0.9)mg/L,all much lower than[(14.1±2.6)pg/mL,(10.2±1.8)pg/mL and(6.3±1.3)mg/L,respectively,P<0.05]in the control group.Conclusion GLP-1RA,semaglutide,in treatment of patients with T2DM and NASH could remarkably improve glucose and lipid metabolism,which might be due to inhibition of body inflammatory reactions.

李甜甜;吴岩

222000 江苏省连云港市 徐州医科大学附属连云港医院/连云港市第一人民医院全科医学科222000 江苏省连云港市 徐州医科大学附属连云港医院/连云港市第一人民医院全科医学科

非酒精性脂肪性肝炎2型糖尿病胰高血糖素样肽-1受体激动剂糖代谢脂代谢治疗

Non-alcoholic steatohepatitisType 2 diabetes mellitusGlucagon-like peptide-1 receptor agonistGlucose metabolismLipid metabolismTherapy

《实用肝脏病杂志》 2026 (5)

673-676,4

江苏省自然科学基金资助项目(编号:SBK2023050003)

10.3969/j.issn.1672-5069.2026.05.009

评论